Blackbird-Backed Telehealth Startup Eucalyptus Sells for $1.6 Billion to US Listed Rival

Why It Matters

The acquisition gives Hims & Hers immediate entry into the Australian and Japanese markets and strengthens its global consumer health platform, accelerating its path to becoming a leading worldwide health brand. It also demonstrates the scaling potential of telehealth firms despite ongoing profitability challenges.

Key Takeaways

• Deal values Eucalyptus at $1.6 bn, Hims & Hers pays $1.15 bn
• ARR exceeds $450 m, triple‑digit YoY growth 2025
• Founder Tim Doyle joins Hims as SVP International, earns $160 m
• Acquisition expands Hims into Australia, Japan, Europe, Canada
• Earn‑out extends to 2029, linking payment to performance

Pulse Analysis

The telehealth sector has entered a phase of rapid consolidation as investors chase scale and geographic reach. Hims & Hers, already a public consumer‑health player, is leveraging the Eucalyptus deal to accelerate its international footprint, a strategy echoed by rivals such as Teladoc and Babylon. By acquiring a company with proven brand segmentation—men’s health, women’s weight loss, fertility, and prescription skincare—Hims gains ready‑made market entry points and a diversified revenue base, reducing reliance on its core U.S. offerings.

Eucalyptus built its business on a multi‑brand model that tailors products to distinct demographic groups, driving an ARR north of $450 million and triple‑digit year‑on‑year growth in 2025. Although the firm posted a modest after‑tax loss, its strong top‑line momentum and deep data on consumer health preferences make it an attractive asset for a platform seeking to personalize care at scale. The $240 million upfront cash, combined with deferred and performance‑based payments, reflects confidence in sustaining growth while mitigating integration risk.

For investors, the transaction signals that public health‑tech companies are willing to pay premium valuations for proven growth engines, even when profitability remains elusive. Hims & Hers’ market cap of $3.6 billion and a 2.5% share dip suggest short‑term market caution, but the expanded presence in Australia, Japan, and key European markets positions the combined entity to capture rising demand for affordable, digitally delivered healthcare. Success will hinge on seamless brand integration, regulatory navigation, and maintaining the high ARR growth that justified the $1.6 bn valuation.